Inclusion Criteria

A. Control Group

1. Aged 18 to 80 years, with no restriction on sex.
2. No current or past history of a psychiatric disorder meeting ICD-10 or DSM-5 criteria.
3. No current or past history of central nervous system disease, such as primary Parkinson's disease or epilepsy, and no severe physical illness.
4. No use within the 3 months before screening of medications that may cause extrapyramidal symptoms, such as antipsychotics or certain antiemetic medications.
5. Sufficient visual, auditory, and cognitive ability to understand and cooperate with the standardized device-side assessment task sequence.
6. Full understanding of the purpose and exploratory research nature of the study, voluntary participation, and provision of written informed consent.

B. EPS Disease Group

1. Aged 18 to 80 years, with no restriction on sex.

2. Diagnosis of schizophrenia or a related psychotic disorder according to ICD-10 criteria.

3. Regular treatment with one or more antipsychotic medications for at least 4 weeks.

4. Clinically confirmed antipsychotic-induced extrapyramidal symptoms meeting at least one of the following criteria:

   1. Drug-induced parkinsonism: a total score of 2 or higher on Items 1, 2, 3, 4, 5, and 9 of the Simpson-Angus Scale (SAS).
   2. Akathisia: a score of 2 or higher on the Global Clinical Assessment item of the Barnes Akathisia Rating Scale (BARS).
   3. Tardive dyskinesia: a score of 3 or higher on any one of Items 1 through 7 of the Abnormal Involuntary Movement Scale (AIMS), or a score of 2 or higher on any two of these items.

5. Sufficient visual, auditory, and cognitive ability to understand and cooperate with the standardized device-side assessment task sequence.

6. Full understanding of the purpose and exploratory research nature of the study, voluntary participation, and provision of written informed consent by the participant or, where applicable, the participant's legal guardian.

Exclusion Criteria

The following exclusion criteria apply to both groups:

1. Primary neurological or organic movement disorders that may affect the assessment results, such as primary Parkinson's disease, Huntington's disease, Wilson's disease, or sequelae of stroke.
2. Severe musculoskeletal disease, recent fracture, limb disability, or other physical conditions that prevent completion of the required assessment tasks.
3. Acute exacerbation of psychiatric symptoms with severe agitation, impulsivity, stupor, or severe cognitive impairment that prevents safe and adequate cooperation with the assessment.
4. Severe deformity of the face or tested limbs, large dark-colored tattoos, or severe non-removable occlusion that may substantially interfere with computer-vision-based assessment.
5. Poorly fitting removable dentures or frequent compensatory oral movements that may interfere with objective assessment of orofacial movements.
6. Any condition that, in the investigator's judgment, may affect participant safety, substantially compromise data quality, or make the individual unsuitable for participation.